Search
Idiopathic Pulmonary Fibrosis Clinical Trials
A listing of 27 Idiopathic Pulmonary Fibrosis clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 27
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Idiopathic Pulmonary Fibrosis
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 27 active clinical trials seeking participants for Idiopathic Pulmonary Fibrosis research studies. The states with the highest number of trials for Idiopathic Pulmonary Fibrosis participants are California, Florida, Texas and Pennsylvania.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Transcranial Magnetic Stimulation (TMS) for Obsessive Compulsive Disorder (OCD)
Recruiting
Transcranial magnetic stimulation (TMS) is an FDA-approved, non-invasive form of brain stimulation for OCD. TMS has been shown to be an effective form of treatment in individuals with OCD. By using a form of TMS termed theta-burst stimulation (TBS), we hope that this will result in a more effective treatment by producing faster symptom reduction. We are trialing a novel form of accelerated TMS, where we will deliver ten 10-minute sessions per day, for 5 days. This study will compare the efficacy of TMS for OCD at two distinct brain regions. Participants will be randomized into one of two study groups, and receive stimulation at either the DMPFC or R-OFC. Both regions have been linked to OCD by research. Patients that don't respond to their study region will have the option to receive stimulation at the other region.
Conditions:
Obsessive-Compulsive Disorder
Obsessive Compulsive Disorder
Obsessive Compulsive Disorder (OCD)
Obsessive-Compulsive Disorder (OCD)
Obsessive-compulsive Disorders and Symptoms
Featured Trial
High Triglyceride Clinical Research Study
Recruiting
Living with high triglycerides? See if our clinical study is right for you.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.
Conditions:
High Triglycerides
High Triglyceride Level
Hypertriglyceridemia
Elevated Triglycerides
Triglycerides High
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
This study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study. The purpose of this study is to find out whether a medicine called BI 1819479 helps people with IPF. 3 different doses of BI 1819479 are tested in this study.
Participants are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1819479. Parti... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/03/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +85 locations
Conditions: Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
01/27/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +499 locations
Conditions: Idiopathic Pulmonary Fibrosis
Xenon MRI and Progressive ILD
Recruiting
The XENON ILD study is a single arm, un-blinded study at Duke University enrolling patients with non-idiopathic pulmonary fibrosis (IPF) progressive fibrosis (PF) interstitial lung disease (ILD). Patients who meet criteria for ILD-progression (defined below in inclusion/exclusion criteria) will be consented prior to the initiation of anti-fibrotic therapy. Subjects will undergo an approximately hour long comprehensive MRI protocol, including administration of multiple doses of hyperpolarized 129... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Duke University, Durham, North Carolina
Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Oral Ifetroban in Patients with Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
01/23/2025
Locations: University of California San Francisco, San Francisco, California +15 locations
Conditions: Idiopathic Pulmonary Fibrosis
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Gender:
ALL
Ages:
40 years and above
Trial Updated:
01/22/2025
Locations: The Kirklin Clinic of University of Alabama Birmingham Hospital, Birmingham, Alabama +28 locations
Conditions: Idiopathic Pulmonary Fibrosis
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
Recruiting
Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part. The purpose of this study is to find out how well BI 1839100 helps reduce coughing in people with IPF or PPF.
Participants who have IPF are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1839100. Participants in 1 group get placebo. Placebo look... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +92 locations
Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: GSK Investigational Site, Newport Beach, California +50 locations
Conditions: Idiopathic Pulmonary Fibrosis
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
Recruiting
We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of these diseases.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Disorder
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Recruiting
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/14/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +111 locations
Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Recruiting
This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550 (study 1305-0014 or 1305-0023).
The goal of this study is to find out how well people with pulmonary fibrosis tolerate long- term treatment with nerandomilast. The study also tests whether nerandomilast improves lung function and prolongs the time until sympto... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +335 locations
Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
Recruiting
The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
01/07/2025
Locations: UPMC Presbyterian, Pittsburgh, Pennsylvania +1 locations
Conditions: Idiopathic Pulmonary Fibrosis, Emphysema or COPD
Mechanisms of Familial Pulmonary Fibrosis
Recruiting
This a prospective, longitudinal study of first-degree family members of patients diagnosed with familial interstitial pneumonia (FIP). FIP is the familial form of idiopathic pulmonary fibrosis (IPF), which is defined as 2 or more bloodline relatives which have a diagnosis of idiopathic interstitial pneumonia (IIP). The most common form of idiopathic interstitial pneumonia in FIP families is IPF (approximately 70%). The inheritance pattern in FIP is consistent with autosomal dominant inheritance... Read More
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
12/18/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Familial Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Familial Interstitial Pneumonia
1 - 12 of 27